|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500115393 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-25 11:49:45 |
|
注册时间: Date of Registration: |
2025-12-25 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
早中期KOA肾虚证演变临床特征及生物标志物研究 |
|
Public title: |
Clinical Characteristics and Biomarker Research on the Evolution of Kidney Deficiency Syndrome in Early and Middle Stages of Knee Osteoarthritis (KOA) |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
早中期KOA肾虚证演变临床特征及生物标志物研究 |
|
Scientific title: |
Clinical Characteristics and Biomarker Research on the Evolution of Kidney Deficiency Syndrome in Early and Middle Stages of Knee Osteoarthritis (KOA) |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张还添 |
研究负责人: |
张还添 |
|
Applicant: |
Huantian Zhang |
Study leader: |
Huantian Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 188 2079 7138 |
研究负责人电话: Study leader's telephone: |
+86 188 2079 7138 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhanghuantian@jnu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
zhanghuantian@jnu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省广州市天河区黄埔大道西613号暨南大学附属第一医院 |
研究负责人通讯地址: |
广东省广州市天河区黄埔大道西613号暨南大学附属第一医院 |
|
Applicant address: |
The First Affiliated Hospital of Jinan University, No. 613, West Huangpu Avenue, Tianhe District, Guangzhou City, Guangdong Province |
Study leader's address: |
The First Affiliated Hospital of Jinan University, No. 613, West Huangpu Avenue, Tianhe District, Guangzhou City, Guangdong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
暨南大学附属第一医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Jinan University |
||
|
研究负责人所在单位: |
暨南大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Jinan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY-2025-304 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
暨南大学附属第一医院涉人的科学研究伦理审查委员会 |
||
|
Name of the ethic committee: |
The Ethics Review Committee for Human Research of the First Affiliated Hospital of Jinan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-11-05 00:00:00 |
||
|
伦理委员会联系人: |
郑丹娜 |
||
|
Contact Name of the ethic committee: |
Danna Zheng |
||
|
伦理委员会联系地址: |
广东省广州市天河区黄埔大道西601号 |
||
|
Contact Address of the ethic committee: |
No. 601, West Huangpu Road, Tianhe District, Guangzhou City, Guangdong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 38688462 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
ofyyllbgs@jnu.edu.cn |
|
研究实施负责(组长)单位: |
暨南大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Jinan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省广州市天河区黄埔大道西613号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 613, Huangpu Avenue West, Tianhe District, Guangzhou City, Guangdong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家级 - 国家自然科学基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation of China |
||||||||||||||||||||||
|
Target disease: |
Osteoarthritis |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
构建广东省人群KOA肾虚证的大样本队列数据库和生物样本库,明确肾虚证的演变规律,辨识一批KOA肾虚证相关的新型生物标志物。 |
||||||||||||||||||||||
|
Objectives of Study: |
Establish a large-scale cohort database and biological sample bank for the KOA kidney deficiency syndrome in the Guangdong population, clarify the evolution pattern of the kidney deficiency syndrome, and identify a group of novel biological markers related to KOA kidney deficiency syndrome. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
KOA肾虚证受试者纳入标准: ① 年龄:60-75岁,性别不限。 ② 根据x线/磁共振成像(MRI)/临床症状诊断为OA。 ③ Kellgren & Lawrence分级0-Ⅱ级之间。 ④ 符合肾虚证(肾阴虚、肾阳虚、肾阴阳两虚)中医辨证标准。 ⑤ 同意参加此项研究并且签署知情同意书。 健康对照组纳入标准: ① 年龄:60-75岁,性别不限。 ② 不符合KOA诊断标准。 ③ 不符合肾虚证诊断标准。 ④ 身体状况良好,无其他影响身体健康的重大疾病。 ⑤ 同意参加此项研究并且签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
Inclusion criteria for KOA patients with kidney deficiency syndrome: 1. Age: 60-75 years old, gender not restricted. 2. Diagnosed with OA based on X-ray/MRI/clinical symptoms. 3. Kellgren & Lawrence grade between 0 and II. 4. Meet the diagnostic criteria for kidney deficiency syndrome (kidney yin deficiency, kidney yang deficiency, or kidney yin-yang deficiency) in traditional Chinese medicine. 5. Agree to participate in this study and sign the informed consent form. Inclusion criteria for the healthy control group: 1. Age: 60-75 years old, gender not restricted. 2. Do not meet the diagnostic criteria for KOA. 3. Do not meet the diagnostic criteria for kidney deficiency syndrome. 4. Good physical condition, without other major diseases affecting health. 5. Agree to participate in this study and sign the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
① 继发性关节炎:类风湿性关节炎、强直性脊柱炎、痛风性关节炎、感染性关节炎、创伤性关节炎等。 ② 严重关节结构异常:膝关节畸形、残废、丧失功能者。 ③ 合并系统性疾病:严重心、肝、肾衰竭,恶性肿瘤,血液系统疾病,免疫缺陷、结核、血友病、精神疾病等疾病。 ④ 过去1月内接受过关节腔注射(如激素、透明质酸)、长期口服激素或免疫抑制剂。 ⑤ 有妊娠可能或计划妊娠者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Secondary arthritis: Rheumatoid arthritis, ankylosing spondylitis, gouty arthritis, infectious arthritis, traumatic arthritis, etc. 2.Severe joint structural abnormalities: Deformed, disabled, or dysfunctional knee joints. 3. Complicated with systemic diseases: Severe heart, liver, or kidney failure, malignant tumors, blood system diseases, immune deficiencies, tuberculosis, hemophilia, mental disorders, etc. 4. Received joint cavity injections (such as hormones, hyaluronic acid) within the past month, or have been taking long-term hormones or immunosuppressants. 5.Women who may be pregnant or planning to get pregnant. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-01-01 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集与管理由病理报告表及电子病例系统组成 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection and management consist of pathological report forms and electronic case systems. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |